Please login to the form below

Not currently logged in
Email:
Password:

Earnings down for Cephalon

US-based biopharmaceutical firm Cephalon has recorded a 14 per cent decrease in net profit despite rising sales over the second quarter of 2011

US-based biopharmaceutical firm Cephalon has recorded a 14 per cent decrease in net profit despite rising sales over the second quarter of 2011.

The company had a net profit $142.6m compared to $165.3m in 2010.

Sales increased by 2 per cent however, with total revenue reported as $730.1m.

The company's oncology division had a particular impact on the company's performance, with sales up 22 per cent to $158.8m. This was helped by significant sales of chronic lymphocytic leukaemia treatment Treanda (bendamustine hydrochloride).

Cephalon is currently in the middle of an acquisition by Teva Pharmaceutical. In May, 2010, the companies entered into an agreement where Teva would acquire all outstanding shares in Cephalon for $81.50 per share in cash, a total value of around $6.8bn

In the quarterly report, Kevin Buchi, CEO, Cephalon, said: "We continue to work with both US and European authorities to obtain all necessary regulatory approvals in order to close the transaction with Teva."

3rd August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is a creative agency specialising in healthcare communication and understanding people's personality types....

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics